tbuckley/cabot-search huggingface dataset:
Sleep apnea and risk of osteoporosis – A nationwide population-based study
Authors: Hung-Ling Huang, Ming-Ju Tsai Tsai, Tai-Huang Lee, Yu-Chieh Chung, Inn-Wen Chong
Journal: European Respiratory Journal (2014)

Rationale   The relationship between sleep apnea (SA) and osteoporosis remains controversial. A small Turkish case-control study found decreased bone density in male with obstructive SA, whereas a French study showed higher bone density in elders with obstructive SA. We therefore conducted a study using Taiwan National Health Insurance (NHI) database.   Methods   From a database of 1 million subjects randomly sampled from individuals enrolled in the NHI system in 2005, we identified adult patients with a diagnosis of SA after polysomnography. We excluded those having osteoporosis prior to SA. Each SA patient was matched to 30 randomly-selected, age- and gender-matched control subjects without any diagnosis of SA. The control subjects were assigned with the same index dates. We used Chi-square test and survival analysis to compare the incidences and cumulative incidences of osteoporosis in both groups and Kaplan-Meier method and log-rank test for cumulative incidences analysis.   Results   We identified 1764 SA patients and 52920 control subjects. No significant difference was noted in the incidence and the cumulative incidence of osteoporosis between two cohorts (p = 0.4190 and 0.8005, respectively). In multivariable Cox regression analysis, SA was not a significant risk factor or protective factor for the development of osteoporosis after adjusting for age, job and comorbidities (hazard ratio = 1.02 [95% confidence incidence: 0.67 – 1.54], p = 0.9438).   Conclusions   Our study revealed no significant difference in osteoporosis incidence between SA patients and control subjects, even in subgroup analyses. Further detailed analysis is needed to clarify the association between SA and osteoporosis.
Low-income is a predictive factor of failure associated with smoking cessation at a public clinic in Brazil
Authors: Rafaella F. Xavier, Dionei Ramos, Giovana N.B. Ferrari, Juliana T. Ito, Fernanda M.M. Rodrigues, Alessandra C. Toledo, Ercy M.C. Ramos
Journal: European Respiratory Journal (2011)

Smoking cessation programs (SCP) are the main way to reduce tobacco related mortality and morbidity. The search for predictors of failure or success specific to a population with special characteristics, such as Brazilians, should be the first step in the development of SCP national. We evaluated the demographic characteristics and factors influencing the failure or success of quitting among participants in a SCP. This retrospective study was conducted from 2005-2009 in a SCP based on cognitive behavioral treatment associated or not with medication therapy consisted in 20 meetings during 12 months. After that the individuals were invited to answer a socio-economic questionnaire by telephone. A total of 158 individuals were included in this study and 65 agreed to answer a socio-economic questionnaire (aged=49±10, pack-years index=35±24, women=63%). Regarding education level: 50% had primary education, 29% had high school and 21% had university education. Accordance with socio-economic questionnaire 14% of the individuals were at class A2, 21% at class B2, 54% at class C and 11% at class D. After the fourth meeting 47,7% of individuals attempt to quit but only 32% of this group remained abstinent after the end of the SCP. Thereby the total quit rate at 12 months was 15%. The failure in smoking cessation at the end of 12 months was increased in individuals from social class C (p
Abstract 11478: Ischemic Stroke After Antithrombotics Withdrawal and Its Impact on Neurological Deterioration
Authors: Jeong Min Kim, Keun-Hwa Jung, Taejun Kim, Keon Joo Lee, Hee-Kwon Park, Kon Chu
Journal: Circulation (2014)

Introduction: Clinical characteristics of stroke after antithrombotics withdrawal and functional outcome have not been studied. Hypothesis: We tried to evaluate clinical significance of antithrombotics withdrawal in stroke occurrence and outcome. Methods: Between January 1st 2009, and March 1st 2012, the acute stroke patients who admitted in Seoul National University Hospital within seven days after symptom onset were included. We defined stroke after antithrombotics withdrawal (SAW) as those patients who had maintained antiplatelet or anticoagulant regularly but ceased their medication before stroke onset within 60 days. We reviewed their clinical characteristics as well as the reason of medication cessation, type of medication, and duration between medications hold and stroke onset. To evaluate the effect of antithrombotics withdrawal in stroke outcome, we compared SAW with those patients who experienced stroke on regular medication. Results: Among 1635 acute stroke patients, 53 patients (3.6%) were ide...
Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Reactive and Neoplastic Lymphoid Cells
Authors: Maryalice Stetler-Stevenson, Adnan Mansoor, Megan Lim, Paula Fukushima, John Kehrl, Gerald Marti, Konrad Ptaszynski, Jiun Wang, William G. Stetler-Stevenson
Journal: Blood (1997)
Nonmalignancy of Hybrids Derived From Two Mouse Malignant Cells. II. Analysis of Malignancy of LM (TK-) Cl 1D Parental Cells
Authors: Jacques Jami, Evelyne Ritz
Journal: JNCI Journal of the National Cancer Institute (1975)

The possibility that Cl 1D cell line, an L-cell line derivative, was a mixture of malignant and nonmalignant cells was investigated because previous experiments showed that some hybrids derived from Cl 1D and tumor cell lines grew in vivo, whereas others apparently did not have that capacity. More highly malignant Cl 1D cells were not selected by animal passage of tumors obtained from inoculation of cultures. The tumor-producing capacity of this line (10%) was greatly increased (81%) in X-irradiated hosts. These observations suggested that the low capacity of Cl 1D cells to grow in vivo did not result from varying degrees of malignancy but mainly from interference of immunogenetic factors between cells and their inbred hosts of origin. Numerous hybrids between tumor and host cells were in all tumors examined.
Scientists propose a new theory for the pathogenesis of Alzheimer's disease
Authors: S. Gottlieb
Journal: BMJ (2001)

<h3>ABSTRACT</h3> Microsatellite instability (MSI) is a well-established prognostic and predictive biomarker in certain types of cancers. MSI detection using tumour tissue is often limited by the availability of specimens. Next generation sequencing (NGS)-based MSI detection in plasma cell-free DNA (cfDNA) is challenged by a much lower signal-to-noise ratio. We developed a highly accurate cfDNA MSI detection method called bMSI-CAST (blood MSI Caller Adjusted with Sequence duplicaTes), with improvement on three features including a set of locus selection principles ensuring loci with high robustness and compatibility across sequencing platforms, an MSI-specific duplicate removal strategy, and a calling algorithm that dynamically matches baselines with a broad range of duplication levels. Analytical validation via MSI-high (MSI-H) cell gDNA showed an LOD of 0.15%. Furthermore, in an analysis of 95 evaluable cfDNA samples from patients with gastrointestinal cancers, bMSI-CAST exhibited a positive predictive agreement (PPA) of 92.9% (39/42) and negative predictive agreement (NPA) of 100% (53/53) with tissue MSI-PCR. In conclusion, bMSI-CAST provides novel and advanced solutions to key aspects fundamental to cfDNA MSI calling but not sufficiently addressed by existing methods, and it is a validated method ready to be applied to aid clinical decisions for cancer patients.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
Authors: Raman Desikan, Bart Barlogie, Jeffrey Sawyer, Dan Ayers, Guido Tricot, Ashraf Badros, Maurizio Zangari, Nikhil C. Munshi, Elias Anaissie, Dan Spoon, David Siegel, Sundar Jagannath, David Vesole, Joshua Epstein, John Shaughnessy, Athanasios Fassas, Seah Lim, Paula Roberson, John Crowley
Journal: Blood (2000)
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study.
Authors: M. Bitzer, M. Horger, M. P. Ebert, T. Ganten, M. A. Woerns, B. Hauns, A. Mais, R. Jankowsky, B. Hentsch, U. M. Lauer
Journal: Journal of Clinical Oncology (2010)

e14661 Background: Resminostat (4SC-201) is a novel specific pan-HDAC inhibitor under clinical evaluation as mono or combination therapy for solid and hematological malignancies. Here, we describe the first results of a phase II study started in 2009 to evaluate safety, tolerability and efficacy of resminostat in patients with HCC exhibiting progressive disease under sorafenib first-line therapy. Methods: Patients with advanced stage HCC, BCLC classes B or C are included in a multicenter, open-label, two-arm parallel group trial. Arm A consists of a combination treatment of resminostat and sorafenib with escalating dose levels to evaluate potential dose-limiting toxicities (DLT) and the maximum tolerated dose. Patients in Arm B receive resminostat alone (600 mg) in 14-day cycles each consisting of 5 consecutive treatment days (D1-5) followed by a 9-day rest period. Primary objective is to determine the progression-free-survival rate after 12 weeks (6 cycles). Secondary objectives include safety and tolerability parameters, tumor response, assessment of pharmacokinetics and biomarkers. Results: To date, 8 pts were treated either with resminostat alone or in the combination arm with sorafenib at the first two dose levels consisting of 200 mg or 400 mg resminostat (D1-5, once daily) and sorafenib 400 mg (continuous, twice daily). The majority of adverse events include gastrointestinal disorders such as nausea and vomiting; these symptoms ranged from mild to moderate intensity. The most prominent adverse event was a skin reaction of grade 2 under the combination therapy. Up to now, there were no DLT, defined as grade 4 hematological or grade 3/4 nonhematologic toxicity occurring in the first cycle. Following repeated dose administration, high plasma exposure of resminostat as monotherapy or in combination with sorafenib was obtained, indicating good bioavailability and consistency with phase I data. Conclusions: Preliminary clinical data confirmed the favorable oral drug profile and good tolerability of resminostat either in mono- or in combination treatment with sorafenib. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration 4SC AG Bayer HealthCare Germany 4SC AG
147. Chemical Enhancers of Non-Viral Salivary Gland Gene Transfer
Authors: Beth M. McMahon, Yen-Ju Chen, Edmund J. Niedzinski, Michael J. Bennett
Journal: Molecular Therapy (2004)

Gene transfer to the major salivary glands is an attractive method for the systemic delivery of therapeutic proteins. To date, non-viral gene transfer to these glands has resulted in inadequate systemic protein concentrations. We believe that identification of the barriers responsible for this inefficient transfection will enable enhanced non-viral gene transfer in salivary glands and other tissues. Our efforts to identify and transcend these barriers have resulted in the discovery of a group of compounds that enhance non-viral, salivary gland gene transfer by four orders of magnitude relative to unformulated DNA. These data as well as data directed towards understanding the mechanism-of-action responsible for the observed enhancement in non-viral gene transfer will be presented.
PTX3 as a component of innate immunity in the role of captopril in acute lung injury induced by bacterial endotoxin
Authors: Xiaolin He, Shi Wang, Shuyue Xia, Xu Liu, Ning Song
Journal: European Respiratory Journal (2011)

Objective: Innate immunity is an important mechanism for the development of acute lung injury (ALI). Long pentraxin PTX3 is an inflammatory mediator and a component of innate immunity. Recent evidence implies that angiotensin-converting enzyme (ACE) plays an important role in the pathogenesis of ALI. We speculated that inhibition of ACE play the protective effect on ALI through the presence of PTX3, therefore, protect the lung from severe injury.

Methods: Lung injury was induced by intratracheal instillation of lipopolysaccharide (LPS) in rats, followed by i.p. administration of captopril, an ACE inhibitor, or saline control, and the PTX3 expression, fibrin deposition, tissue factor expression and lung injury were determined. Local and systemic inflammatory responses were assessed by measuring cytokines in the lung and plasma.

Results: Treatment with captopril dramatically attenuated LPS-induced lung injury, alveolar fibrin deposition and inflammatory cell infiltration 6 h after LPS challenge compared to that in the saline control rats. Local and systemic PTX3 expression were significantly decreased by the captopril therapy, accompanied by decreased interleukin (IL)-6, IL-10 and monocyte chemoattractant protein-1 levels in the plasma.

Conclusion: These results support that inhibition of ACE with its clinically used inhibitor offers protective effects on ALI; PTX3, acting as both anti-inflammation component and the component of innate immunity, may reflect severity of lung injury and serve as the potential therapeutic “target” during ALI. Captopril treatment through the presence of PTX3 could be a potential mechanism that mediates lung injury.
317. DNA Damage and Homologous Recombination Regulate the Frequency and Process of Targeted Gene Repair
Authors: Eric B. Kmiec, Luciana Ferrara, Katie Maguire, Hetal Parekh-Olmedo, Tim Schwartz
Journal: Molecular Therapy (2004)

The pathway followed by targeted gene repair is not fully elucidated. In its simplest iteration, the process is viewed as being initiated by the introduction of short (25–75 bases) synthetic single-stranded oligonucleotides into a mammalian cell. The oligonucleotide aligns in homologous register with the target gene using the underlying sequence complementarity as a guide. Once positioned properly, a single mismatched base pair is created between the oligonucleotide and the target site. The structural changes and altered DNA conformation that clearly take place during the pairing phase attract proteins involved in DNA repair pathway. Here we demonstrate the involvement of the homologous recombination (HR) process in gene repair. By using a phenotypic readout assay system, where an eGFP gene containing a single point mutation is integrated into DLD-1 cells, we observe between 0.7 and 1.5% correction of the mutation. Gene repair is assessed by FACS analyses, cell sorting and confirmatory DNA sequencing of the target gene. When the cells are arrested in S phase as a result of DNA damage incurred by the presence of hydroxyurea or thymidine, the level of gene repair increases 3 to 4 fold. Addition of the anticancer drug VP16 (etopside) or Camptothecin (CPT) induces a similar response for both episomal or chromosomal targets. Synchronized cells are also more amenable to the gene repair reaction once released into S phase and a synergistic effect is seen when cell synchronization is coupled to the addition of HU or thymidine or CPT. These results suggest that DNA damage at the replication fork stimulates the homologous recombination pathway to act upon strand lesions (double strand breaks, etc.), enabling a more efficient gene repair reaction to take place. Agents or enzymes that induce the double strand breaks repair response are also quite effective in regulating and elevating the frequency of gene repair. Taken together, we propose that the factors and/or protein activated by recombination induced by replication inhibition (RIRI), particularly those involved in HR, are capable of enhancing the frequency of gene repair in mammalian cells.
Production of Tumors in Mice With Tars From City Air Dusts<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>
Authors: Joseph Leiter, M. J. Shear
Journal: JNCI Journal of the National Cancer Institute (1942)

Production of Tumors in Mice With Tars From City Air Dusts Joseph Leiter, Joseph Leiter assistant chemist Search for other works by this author on: Oxford Academic PubMed Google Scholar M. J. Shear M. J. Shear principal biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 2, October 1942, Pages 167–174, https://doi.org/10.1093/jnci/3.2.167 Published: 01 October 1942
Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study
Authors: R L Suddath, M F Casanova, T E Goldberg, D G Daniel, J R Kelsoe, D R Weinberger
Journal: American Journal of Psychiatry (1989)

Although numerous studies have confirmed the presence of larger cerebral ventricles in schizophrenia, the locus of tissue loss remains elusive. By analyzing magnetic resonance scans with computerized image analysis, the authors determined gray and white matter volumes in the temporal lobes and prefrontal regions of 17 patients with schizophrenia and 17 age- and sex-matched normal subjects. The volume of temporal lobe gray matter was 20% smaller in the patients than in the control subjects. The lateral ventricular volume was 67% larger in the patients and, when normalized for brain size, correlated inversely with the volume of temporal lobe gray matter.
THE ESTIMATION OF CARDIAC FUNCTION BY SIMPLE CLINICAL METHODS
Authors: Emanuel Messinger
Journal: Annals of Internal Medicine (1937)

Article1 January 1937THE ESTIMATION OF CARDIAC FUNCTION BY SIMPLE CLINICAL METHODSEMANUEL MESSINGER, A.B., M.D.EMANUEL MESSINGER, A.B., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-7-986 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe problem of determining the functional impairment, or conversely the cardiac reserve of ambulatory cardiac patients has always been a baffling one. Even with the use of all our modern laboratory adjuncts—the fluoroscope, roentgen-ray measurements of the heart, and lastly the electrocardiogram, in addition to all available clinical methods, one is often at a loss to decide just where in the scale of impairment of cardiovascular function a particular patient belongs. This difficulty of course arises chiefly in the case of the strictly ambulatory cardiac patient, since those patients who show evidences ofdecompensationeither at rest or after moderate... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Cloud, Minnesota*Received for publication September 14, 1936.Published with the permission of the Medical Director of the Veterans Administration, who assumes no responsibility for the opinions expressed or the conclusions drawn by the writer. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEstimation of cardiopulmonary functional capacity by means of oxygen debt studies 1 January 1937Volume 10, Issue 7Page: 986-999KeywordsElectrocardiographyHeartResearch laboratories Issue Published: 1 January 1937 PDF downloadLoading ...
Differences Between Patients Receiving Peritoneal Dialysis vs Hemodialysis
Authors: Mahesh Goel
Journal: JAMA (2004)

To the Editor: Dr Rubin and colleagues1 reported that patients receiving peritoneal dialysis rated their care higher than did patients receiving hemodialysis. We are concerned that the authors did not account for several factors related to the choice of peritoneal dialysis vs hemodialysis.
Retraction: Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity
Authors: Loc T. Nguyen, Bogoljub Ciric, Virginia P. Van Keulen, Moses Rodriguez, Larry R. Pease, Koji Tamada, Dallas B. Flies, Lieping Chen
Journal: Cancer Research (2010)
Abstract MP33: The Deaf Weight Wise Study: A Unique Clinical Trial of Health Behavior Modification with Deaf Adults
Authors: Steven Barnett, Erika Sutter, Thomas Pearson
Journal: Circulation (2014)

Introduction: Deaf people who use American Sign Language (ASL) comprise linguistic and cultural minority populations without access to language-concordant health information and healthcare. Deaf ASL users are rarely included in health research or public health surveillance. Recent research with Deaf ASL users found a higher prevalence of obesity than in the general population. No randomized trials of lifestyle modification or weight reduction have ever been attempted with Deaf ASL users. Methods: We worked with the Rochester (NY) Deaf community to adapt a 16-week healthy lifestyle program previously shown to be effective with hearing people. We adapted the curriculum and research measures to be culturally and linguistically appropriate. We used a group intervention format recommended by our Deaf partners, and trained group leaders who were Deaf, ASL fluent and had backgrounds in counseling, public health, or healthcare. For this Deaf Weight Wise (DWW) trial, we recruited Deaf adults aged 40-70 with a BMI of 25-45 from community settings, and randomized participants to immediate intervention or intervention delayed 1 year. We will collect data from DWW trial participants over two years. We present analyses of data after 6 months here. Primary outcomes were changes in weight, BMI and scores on two standard measures: Dietary Risk Assessment (DRA) and Physical Activity Assessment (PAA). We used group by time repeated measures ANOVA to examine changes from baseline to 6 months for the immediate group and delayed group (no intervention yet). Hypothesis: The immediate intervention group would have greater reduction in weight and BMI as well as improvement in DRA and PAA scores six months after baseline compared with the delayed intervention group. Results: At baseline, the 104 participants’ mean age was 53.5 years; 68.3% (71 of 104) were female and 91.3% (95/104) were White. Randomization was successful based on baseline data. At 6 months, the immediate group weight changed -3.35kg (1.0 s.e.; p=.002) and BMI changed -1.35 (0.4 s.e.; p≤.0001) compared with the delayed group. Most of the immediate group (58.3%, 28/48) lost ≥ 5% of baseline weight versus 14.3% (8/56) of the delayed group (p≤.0001). Changes in mean DRA (p=.055) and moderate PAA (p=.054) scores numerically favored the immediate group. Conclusions: Deaf Weight Wise is the first randomized controlled trial of a healthy lifestyle program with Deaf ASL users. This culturally appropriate and language accessible behavioral intervention was feasible and highly effective with this underserved and rarely studied population.